

Final - October 16, 2018

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention
1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium
Atlanta, Georgia 30329
October 24-25, 2018

<u>AGENDA ITEM</u>	<u>PURPOSE</u>	<u>PRESIDER/PRESENTER(S)</u>
Wednesday, October 24		
8:00 Welcome & Introductions		Dr. Amanda Cohn (ACIP Executive Secretary; CDC)
8:30 Hepatitis A Vaccines		
Introduction		Dr. Kelly Moore (ACIP, WG Chair)
Background	Information	Dr. Noele Nelson (CDC/NCHHSTP)
Homelessness as a risk group: Evidence to Recommendation	& Discussion	Dr. Mona Doshani (CDC/NCHHSTP)
Framework and GRADE		
Public comment		
Recommendation vote	<u>Vote</u>	Dr. Noele Nelson (CDC/NCHHSTP)
VFC vote	<u>VFC Vote</u>	Dr. Jeanne Santoli (CDC/NCIRD)
10:15	Break	
10:30 Pneumococcal Vaccines		
Introduction		Dr. Grace Lee (ACIP, WG Chair)
PCV13 Impact on IPD and serotype distribution for the remaining disease burden		Dr. Tamara Pilishvili (CDC/NCIRD)
Incidence of non-Invasive Pneumococcal Pneumonia before and after PCV13 recommendation for adults ≥65yo	Information	Mr. Ryan Gierke (CDC/NCIRD)
U.S. trends in pneumonia hospitalizations	& Discussion	Dr. Fernanda Lessa (CDC/NCIRD)
Economic analysis of PCV13 for adults ≥65 year old		Dr. Charles Stoecker (Tulane University School of Public Health and Tropical Medicine)
Preliminary EtR and GRADE. Summary and timeline		Dr. Almea Matanock (CDC/NCIRD)
12:15	Lunch	
1:30 Adult Immunization Schedule		
Introduction	Information &	Dr. Paul Hunter (ACIP, WG Chair)
Proposed 2019 adult immunization schedule	Discussion	Dr. David Kim (CDC/NCIRD)
2:20 Child/Adolescent Immunization Schedule		
Introduction	Information	Dr. Henry Bernstein (ACIP, WG Chair)
Proposed 2019 child and adolescent immunization schedule	& Discussion	Dr. Candice Robinson (CDC/NCIRD)
Public comment		
Immunization schedules recommendations vote	<u>Vote</u>	Drs. David Kim and Candice Robinson (CDC/NCIRD)
3:00	Break	
3:15 Japanese Encephalitis		
Introduction		Dr. Chip Walter (WG chair)
JE vaccine Evidence to Recommendations	Information &	Dr. Susan Hills (CDC/NCEZID)
JE-VC accelerated schedule recommendation for adults	Discussion	Dr. Susan Hills (CDC/NCEZID)
JE-VC pediatric booster and booster dose recommendations		Dr. Susan Hills (CDC/NCEZID)
Conclusions and next steps		Dr. Susan Hills (CDC/NCEZID)
4:15 Anthrax		
Introduction		Dr. David Stephens (ACIP, WG Chair)
NuThrax®	Information	Dr. Paul- Andre de Lame, Mr. Jeff Shearer (Emergent BioSolutions)
Anthrax antitoxin for PEP		Dr. William Bower (CDC/NCEZID)
5:00 Vaccine Supply		
5:05 Public Comment		
5:20 Adjourn		

Final - October 16, 2018

Thursday, October 25

8:00 Agency Updates & Unfinished Business

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

Information

Dr. Nancy Messonnier (CDC/NCIRD); *Ex Officio* Members

8:30 Human Papillomavirus

Introduction

Vaccine safety update - no association with primary ovarian insufficiency

Background - Expanded age indication for 9vHPV GRADE

Impact and economic analyses

Recommendation options

Information & Discussion

Dr. Peter Szilagyi (ACIP, WG Chair)

Ms. Julianne Gee (CDC/NCEZID)

Dr. Lauri Markowitz (CDC/NCIRD)

Dr. Elissa Meites (CDC/NCIRD)

Dr. Harrell Chesson (CDC/NCHHSTP)

Dr. Lauri Markowitz (CDC/NCIRD)

10:15 *Break*

10:45 General Recommendations

Introduction

Background and posted changes since April 2017

Vaccine Administration – Vaccinators with conditions that are contraindications or precautions

Information & Discussion

Dr. Paul Hunter (ACIP, WG Chair)

Dr. Andrew Kroger (CDC/NCIRD)

Dr. Andrew Kroger (CDC/NCIRD)

11:15 Influenza

Introduction

Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy

Fluzone Quadrivalent 0.5-mL dose for children aged 6 through 35 Months

Information & Discussion

Dr. Chip Walter

Dr. Mark Thompson (CDC/NCIRD)

Dr. Monica Mercer (Sanofi Pasteur)

12:15 Rabies

Workgroup update

Information

Dr. Sharon Frey (ACIP, WG Chair)

12:20 Meningococcal

Workgroup Update

Information

Dr. David Stephens (ACIP, WG Chair)

12:25 Pertussis

Introduction to Work Group

Background to current ACIP recommendations (Td and Tdap) and policy considerations for Tdap revaccination

Adacel revaccination safety and immunogenicity

Boostrix revaccination safety and immunogenicity

Information

Dr. Henry Bernstein (ACIP, WG Chair)

Dr. Fiona Havers (CDC/NCIRD)

Dr. David Greenberg (Sanofi Pasteur)

Dr. Leonard Silverstein (GSK)

1:30 Public Comment

1:45 Adjourn

Acronyms

9vHPV	9-Valent Human Papillomavirus Vaccine
CDC	Centers for Disease Control & Prevention
CMS	Centers for Medicare and Medicaid Services
DoD	Department of Defense
DVA	Department of Veterans Affairs
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
IPD	Invasive pneumococcal disease
JE-VC	Vero cell culture-derived Japanese encephalitis vaccine
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NVPO	National Vaccine Program Office
PEP	Post-exposure prophylaxis
PCV13	13-valent pneumococcal conjugate vaccine
Td	Tetanus and diphtheria vaccine
Tdap	Tetanus, diphtheria, and pertussis vaccine
VFC	Vaccines for Children
WG	Work Group